Australia

Neuren Phase 2 trial shows significant improvements in Phelan-McDermid syndrome

Highlights:  * Significant improvement was assessed by both clinicians and caregivers across multiple efficacy measures   * Improvements were consistently seen across clinically important aspects of Phelan-McDermid syndrome, including communication, behaviour, cognition/learning and socialis...

2023-12-18 19:00 1052

Lunit Advances to Stage 2 of Australia's National Breast Cancer Screening Project

* After a successful stage 1, Lunit INSIGHT MMG moves to prospective validation inAustralia's BreastScreen NSW Machine Reading Solution Project SEOUL, South Korea, Dec. 11, 2023 /PRNewswire/ -- Lunit (KRX:328130.KQ), a leading provider of AI-powered solutions for cancer diagnostics and therape...

2023-12-11 22:30 1420

IonOpticks and Newomics broaden chromatography accessibility for Agilent mass specs, with Shimadzu pending

MELBOURNE, Australia, Dec. 6, 2023 /PRNewswire/ -- IonOpticks, the world leader in high performance liquid chromatography for mass spectrometry, is proud to announce an exciting collaboration with Newomics Inc. that has produced an interface solution for their flagship Aurora Series columns and A...

2023-12-07 07:04 1387

Registrational Phase III CLARIFY trial in prostate cancer commences

SYDNEY, Nov. 30, 2023 /PRNewswire/ -- Clarity Pharmaceuticals (ASX: CU6) ("Clarity"), a clinical stage radiopharmaceutical company with a mission to develop next-generation products that improve treatment outcomes for children and adults with cancer, is pleased to announce it has commenced its r...

2023-11-30 22:16 1165

First patient with metastatic prostate cancer to receive 2 doses of Cu-67 SAR-bisPSMA achieves undetectable PSA level

HIGHLIGHTS * Undetectable levels of Prostate Specific Antigen (PSA) have been reported from the first patient with metastatic castrate-resistant prostate cancer (mCRPC) to ever receive two cycles of Clarity's67Cu-SAR-bisPSMA at the 8GBq dose level. PSA is a marker of tumour burden, clinical re...

2023-11-30 21:59 1294

Leading AI decisioning platform Rich Data Co successfully raises $17.5 million in Series B round to accelerate North America expansion

SYDNEY, Nov. 29, 2023 /PRNewswire/ -- Rich Data Co  (RDC) – a leading AI decisioning platform that helps banks make high-quality lending decisions efficiently and safely – has successfully raisedUS$17.5m in its Series B round. The funding round was led by major Austra...

2023-11-30 07:13 1191

Clarity's theranostic prostate cancer trial progresses at the highest dose level cohort

HIGHLIGHTS * Cohort 3 of the theranostic SECuRE trial investigating 64Cu/67 Cu-SAR-bisPSMA in metastatic castrate-resistant prostate cancer (mCRPC) has enrolled and treated 3 participants who received therapy with67Cu-SAR-bisPSMA at the highest dose level of 12GBq.­ * No dose limiting toxicit...

2023-11-29 21:58 1208

Telstra Broadcast Services and BT Announce Strategic Alliance to Enhance Global Network Connectivity 

Initial five-year agreement delivers expanded media and broadcast network footprint acrossAsia-Pacific and key regions worldwide, with enhanced access to global markets    SYDNEY, Nov. 21, 2023 /PRNewswire/ -- Telstra Broadcast Services (TBS) and BT have entered into an initial five-year strateg...

2023-11-21 13:30 1158

First Subject Enrolled in Phase 1 Study of MRX-5

SHANGHAI, Nov. 20, 2023 /PRNewswire/ -- Recently, Shanghai MicuRx Pharmaceuticals Co., Ltd. (hereinafter referred to as "MicuRx") announced that its proprietary antibiotic MRX-5, has enrolled its first subject in the first Phase I clinical trial inAustralia. MRX-5 is a new type of benzodiazepine...

2023-11-20 18:34 1186

HaemaLogiX Announces Appointment of Damian Clarke-Bruce as Managing Director and CEO

SYDNEY, Nov. 13, 2023 /PRNewswire/ -- HaemaLogiX Ltd, a clinical stage Australian biotech, is pleased to announce the appointment ofDamian Clarke-Bruce as Managing Director and CEO, effective13 November 2023. Outgoing CEO Bryce Carmine will remain active in the company, retaining his role as Cha...

2023-11-14 08:27 1029

6clicks GRC Platform Adds Automated Cybersecurity Incident Tracking and Reporting to Meet New SEC Disclosure Requirements

Platform Now Helps Organizations Compile Details of Qualifying Events Centrally for Tracking, Reporting, and Complete Auditability to Ensure Full Compliance and Ease of Management MELBOURNE, Australia, Nov. 13, 2023 /PRNewswire/ -- 6clicks , pioneers of the leading AI-p...

2023-11-14 06:29 1106

PYC'S FOURTH DRUG CANDIDATE HAS DISEASE-MODIFYING POTENTIAL IN POLYCYSTIC KIDNEY DISEASE

* PYC has developed a new drug candidate for the >5 million people worldwide [1] with Polycystic Kidney Disease (PKD) * This drug candidate has demonstrated efficacy in human models derived from the kidneys of patients with end-stage renal failure due to PKD[2] * PKD is a life-changing diseas...

2023-11-13 21:00 1141

Beyond2020 Improves Access to Clean Water for 10,000 Rural Malaysians

* Sustainable water fountains in 25 rural Malaysian communities provide clean, safe water, reducing waterborne illnesses ABU DHABI, UAE, Nov. 9, 2023 /PRNewswire/ -- Beyond2020, the UAE-driven humanitarian initiative, has installed water filters in 25 communities in theSabah and Sarawak regions...

2023-11-10 03:27 2018

Recruitment target achieved for Phase II SAR-Bombesin prostate cancer trial

SYDNEY, Nov. 7, 2023 /PRNewswire/ -- Clarity Pharmaceuticals (ASX: CU6) ("Clarity"), a clinical stage radiopharmaceutical company with a mission to develop next-generation products that improve treatment outcomes for children and adults with cancer, is pleased to announce that 50 patients have no...

2023-11-07 21:58 1024

David Beckham Signs Deal with TEMPUR to Promote The Benefits Of Sleep

LONDON, Nov. 6, 2023 /PRNewswire/ -- TEMPUR, a leading designer, manufacturer, distributor, and retailer of premium bedding products worldwide, has today announced the signing ofDavid Beckham as its newest brand ambassador. 

2023-11-06 11:00 2555

PolyActiva reports promising clinical trial results for its 6-month sustained drug delivery, biodegradable ocular implant in glaucoma patients.

* Melbourne ophthalmology company PolyActiva is developing a unique biodegradable ocular implant that provides 6 months of sustained drug delivery for patients with glaucoma, the second most common cause of irreversible blindness. * The interim Phase 2a results demonstrate a sustained >20% re...

2023-11-03 05:15 426

CHIMERIC THERAPEUTICS ANNOUNCES FDA CLEARANCE OF IND APPLICATION FOR CHM 2101, A NOVEL CDH17 CAR T CELL THERAPY FOR ADVANCED GASTROINTESTINAL CANCERS

* FDA IND Clearance for CHM 2101, a novel 3rd generation CDH17 CAR T cell therapy * Anticipated to be the first CDH17 CAR T cell therapy to enter the clinic * Phase 1A clinical trial to initiate patient enrolment in 2024 * Phase 1A clinical trial will enroll patients with advanced Colorecta...

2023-10-31 19:00 1044

Clarity and PSI kick off SAR-bisPSMA Phase III

SYDNEY, Oct. 26, 2023 /PRNewswire/ -- Clarity Pharmaceuticals (ASX: CU6) ("Clarity"), a clinical stage radiopharmaceutical company with a mission to develop next-generation products that improve treatment outcomes for children and adults with cancer, and PSI CRO AG ("PSI"), a global contract rese...

2023-10-26 21:00 1112

Enfinity Global to partner with Kyushu Electric Power in its operational portfolio in the United States

MIAMI, Oct. 26, 2023 /PRNewswire/ -- Enfinity Global Inc., a leader in renewable energy, today announced a definitive agreement for a minority sale in its 400 MW U.S. operating portfolio to the Japanese utility Kyushu Electric Power Co. Inc. (Kyushu Electric). Upon completion of the deal, Kyushu ...

2023-10-26 14:30 1325

Enfinity Global & ICG complete €400 million equity agreement

MIAMI, Oct. 25, 2023 /PRNewswire/ -- Enfinity Global, a leader in renewable energy, today announced the successful completion of €300 million equity funding from ICG, the global alternative asset manager. Another €100 million of equity funding is expected to close within a one-year period as part...

2023-10-25 21:32 1749
12345 ... 63

Week's Top Stories